Promising results for Somanta’s anticancer candidate

The results from the tests were presented at the 16th International Prostate Cancer Update Conference in Beaver Creek, Colorado, and suggested that the drug may induce slow pan-cell cycle progression and mitotic commitment with a limited expression of G2 arrest.

“Alchemix possesses potent activity across a variety of chemotherapy-resistant human tumors, including prostate cancer,” said Dr Agamemnon Epenetos president and CEO of Somanta. “The study suggests that this effect is probably due to the pan-cell cycle effects, and specifically that multi-level targeting by Alchemix reduces the probability of cancer cells surviving even if they are resistant to other chemotherapy drugs.”